MedTrace Logo

Effect of Evolocumab on Chronic Total Occlusions (EVOLO-CTO)

NCT05623995 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2023-11-13

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effect of proprotein convertase subtilisin/kexin type-9 (PCSK9) inhibitors added to regular statin therapy on target lesion failure (TLF) and arteriosclerosis progression in patients with chronic total occlusions (CTOs) undergoing successful percutaneous coronary intervention (PCI).

Conditions

Interventions

DRUG

PCSK9 inhibitor

Evolocumab per every two weeks, starting at day 1 and up to week 48, added to guideline recommended statin therapy..

DRUG

Statin

Guideline recommended statin therapy.

Sponsors & Collaborators

  • Lin Zhao

    lead OTHER

Principal Investigators

  • Lin Zhao, MD · Beijing Anzhen Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-15
Primary Completion
2024-12-01
Completion
2025-12-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05623995 on ClinicalTrials.gov